Acute myeloid leukemia (AML) is induced by the cooperative action of deregulated genes that perturb self-renewal, proliferation, and differentiation. Internal tandem duplications (ITDs) in the FLT3 receptor tyrosine kinase are common mutations in AML, confer poor prognosis, and stimulate myeloproliferation. AML patient samples with FLT3-ITD express high levels of RUNX1, a transcription factor with known tumor-suppressor function. In this study, to understand this paradox, we investigated the impact of RUNX1 and FLT3-ITD coexpression. FLT3-ITD directly impacts on RUNX1 activity, whereby up-regulated and phosphorylated RUNX1 cooperates with FLT3-ITD to induce AML. Inactivating RUNX1 in tumors releases the differentiation block and down-regulates genes controlling ribosome biogenesis. We identified Hhex as a direct target of RUNX1 and FLT3-ITD stimulation and confirmed high HHEX expression in FLT3-ITD AMLs. HHEX could replace RUNX1 in cooperating with FLT3-ITD to induce AML. These results establish and elucidate the unanticipated oncogenic function of RUNX1 in AML. We predict that blocking RUNX1 activity will greatly enhance current therapeutic approaches using FLT3 inhibitors.
Acute myeloid leukemia (AML) is a clinically heterogeneous group of cancers caused by genetic and epigenetic alterations that cumulatively drive aberrant proliferation and block differentiation of hematopoietic stem and progenitor cells (HSPCs). Cytogenetic and molecular studies have identified several genes that are affected by recurrent somatic mutations in different AML subtypes. This information has led to a greater understanding of AML biology, allowed better risk stratification to guide therapeutic strategies, and provided new targets for drug development (Marcucci et al., 2011; Cancer Genome Atlas Research Network, 2013; Sanders and Valk, 2013). Nevertheless, long-term survival rates for AML remain dismally poor, with relapse being the most frequent cause of therapeutic failure in leukemia (Burnett et al., 2011; Patel et al., 2012). Understanding the intracellular interactions of driver mutations with secondary changes that propel leukemia progression (e.g., block differentiation) and/or confer drug resistance is essential to improve therapeutic outcomes.
One of the most frequent mutations in AML is internal tandem duplication (ITD) of the FLT3 gene, leading to constitutive activation of FLT3 receptor tyrosine (Tyr) kinase (Stirewalt and Radich, 2003; Small, 2006). Although FLT3 mutations do not define a distinct disease entity, they are of high prognostic relevance with strong association with reduced overall survival (Small, 2006; Patel et al., 2012). Analysis of remission clones has demonstrated a high retention frequency of FLT3-ITD mutations and the acquisition of homozygous mutant alleles (uniparental disomy), suggesting that FLT3-ITD signaling provides a key selective advantage to the cancer and to drug resistance (Thiede et al., 2002; Gale et al., 2008; Paguirigan et al., 2015). FLT3-ITD mutations are often secondary to initiating mutations that confer self-renewal properties to the founder clone, such as mutations in DNMT3A, RUNX1, or TET2 (Welch et al., 2012; Genovese et al., 2014; Shlush et al., 2014). Thus, activated FLT3 likely promotes the expansion of a preleukemic clone that subsequently incurs a block in differentiation, the hallmark of acute leukemia. Mouse models support the impact of FLT3-ITD in the induction of abnormal myeloproliferation and have also demonstrated that, alone, it is insufficient to induce acute leukemia (Grundler et al., 2005; Lee et al., 2007; Chu et al., 2012). It is currently unresolved what genetic or epigenetic events are responsible for the profound block in differentiation in AML and whether shared genetic programs acting downstream of FLT3-ITD signaling contribute to this block. An appealing hypothesis is that FLT3-ITD signaling either directly or indirectly impacts the transcriptional circuitry that controls differentiation decisions.
RUNX1 encodes a key transcriptional regulator of hematopoiesis and thus, not surprisingly, is a frequent target of chromosomal translocations and inactivating mutations in both myeloid and lymphoid neoplasms (Niebuhr et al., 2008; Grossmann et al., 2011; Lam and Zhang, 2012). Runx1 inactivation in mouse models has demonstrated critical functions in several blood lineages: maturation of megakaryocytes (Meg), initiation and progression of B cell development, and stage-specific development of T cells (Ichikawa et al., 2004; Collins et al., 2009; Wong et al., 2011b; Niebuhr et al., 2013). In addition, Runx1 has been implicated in the inhibition of self-renewal programs in early HSPCs (Growney et al., 2005; Ross et al., 2012; Lam et al., 2014; Behrens et al., 2016). This latter function likely explains its known tumor suppressor activity, mirrored in the high incidence of inactivating mutations (10–20%) in AML (Osato et al., 1999; Schnittger et al., 2011; Cancer Genome Atlas Research Network, 2013). Early studies have also demonstrated the interplay of RUNX1 with several granulocyte/macrophage (G/M) transcription factors (TFs; e.g., C/EBP, PU.1, and GFI1) during normal myelopoiesis (Rosenbauer and Tenen, 2007), and thus, a popular theory is that reduced levels of RUNX1 activity contributes to the myeloid differentiation block in AML.
During analysis of gene expression patterns within several large AML patient cohorts available through the Leukemia Gene Atlas (Hebestreit et al., 2012), we observed a consistent and significant increase in RUNX1 transcript levels in FLT3-ITDpos samples (Fig. 1 A). Furthermore, RUNX1 inactivation mutations were significantly underrepresented in FLT3-ITDpos AMLs (Fig. 1 B). Thus, we sought to investigate whether high levels of RUNX1 contribute to AML induction and to explore the interaction between FLT3-ITD mutations and RUNX1 activity.
RUNX1 and FLT3-ITD synergize to induce AML with high penetrance and short latency
To test the hypothesis that increased levels of RUNX1 and FLT3-ITD cooperate to induce AML, we established a retroviral transduction/transplantation mouse model (Fig. 2 A). Overexpression of RUNX1 is known to prevent efficient transplantation of HSPCs (Challen and Goodell, 2010). Thus, a vector expressing RUNX1-ERt2 was generated in which RUNX1 activity (RUNX1*) can be induced with 4-hydroxytamoxifen (4-OHT). HSPCs isolated from B6.Runx1Δ/+ mice were cotransduced with two retroviral vectors, one expressing RUNX1-ERt2 coupled with GFP and the other expressing FLT3-ITD and blue fluorescent protein (BFP). Using this protocol, 6–20% double-positive GFP+/BFP+ HSPCs were obtained (Fig. 2 B). Transplanted mice receiving 4-OHT (+RUNX1*) developed a severe hematopoietic malignancy with an extremely short latency and with close to 100% penetrance (Fig. 2 C). Untreated transplanted mice (−RUNX1*) also developed a hematopoietic abnormality but with <50% penetrance, slower latency, and distinct characteristics.
Based on several clinical, cytohistological, and immunophenotypical criteria, the disease that developed in mice of the RUNX1*/FLT3-ITD cohorts could be classified as AML, in contrast to the myeloproliferative neoplasm (MPN) developing in mice with FLT3-ITD and nonactivated RUNX1. Both AML and MPN mice presented with lethargy, shortness of breath, splenomegaly, anemia, and leukocytosis, although leukocyte counts were higher in the MPN cohort (Fig. 2, D and E). Hepatomegaly as well as extensive and diffuse pulmonary infiltrations were restricted to AML in RUNX1*/FLT3-ITD mice, with MPN mice showing only restricted small focal portal and sinusoidal infiltrates (Fig. 2 F and Fig. S1). Examination of the hypercellular BM sections and blood films confirmed a homogenous population of blast cells in AML mice, in contrast to the increased levels of mature G/M in MPN mice (Figs. 2 G and Fig. S1).
Surface markers and gene expression analysis were used to confirm AML and MPN diagnosis. BM and splenic cells of diseased mice from both 4-OHT–treated (AML) and untreated (MPN) cohorts contained high levels of GFP+/BFP+ cells (Fig. 2 H). However, whereas the MPN cells expressed both Gr1 and CD11b antigens (typical of mature myeloid cells and a myeloproliferation), AML cells were negative for both myeloid markers (Fig. 2 I). AML cells were also negative for the myeloid progenitor marker kit as well as markers for B, T, and erythroid (Ery) cells (Fig. 2 J). Gene expression data obtained from the leukemic cells was compared with that from neoplastic cells from either (a) a pro–B cell acute lymphoblastic leukemia (ALL; induced with FLT3-ITD) or (b) an AML (induced with the RUNX1/RUNX1t1 fusion protein) by unsupervised clustering, confirming closer relatedness with the AML samples (Fig. 2 K). Furthermore, we could confirm expression of genes encoding TFs typically expressed in early myeloid cells (Cebpa, Gata2, and Gfi1b; Fig. S2). The AML phenotype in all RUNX1*/FLT-ITD mice was highly reproducible in a total of six independent experiments.
The distinct AML phenotype induced by activation of RUNX1 in conjunction with FLT3-ITD expression, as opposed to the expansion phenotype (myeloproliferation) in FLT3-ITD cells without activated RUNX1, demonstrates the synergistic action of these two events. However, to determine the influence of the B6.Runx1Δ/+ genotype of the donor cells to the disease phenotype, the experiment was performed using B6.Runx1+/+ as well as B6.Runx1Δ/Δ HSPCs. Again, induction of AML was exclusively observed in the activated RUNX1 cohorts (i.e., 4-OHT treated) in both genetic backgrounds, although the latency was prolonged and incidence decreased in the B6.Runx1+/+ background (Fig. 3). This somewhat contradictory result is likely caused by the increased self-renewal capacity of myeloid HSPCs in B6.Runx1Δ/Δ and B6.Runx1Δ/+ backgrounds, resulting in an initial expansion of transduced cells (Growney et al., 2005; Behrens et al., 2016). This would increase the probability of a differentiation-blocked subpopulation emerging after activation of transduced RUNX1. Collectively, this analysis demonstrates an oncogenic activity of RUNX1 in cooperation with FLT3-ITD and also supports an independent tumor suppressor activity of Runx1 in leukemia initiation.
RUNX1 activity is essential for RUNX1*/FLT3-ITD–induced leukemia and its maintenance
To test whether activated RUNX1 is necessary to both initiate and drive disease progression, we evaluated the effect of removing 4-OHT after RUNX1 induction for 5 d (pulse; Fig. 4 A). Transduction frequencies of B6.Runx1Δ/+ HSPCs were comparable with previous experiments (Fig. 4 B). Peripheral blood (PB) samples were taken weekly to monitor the expansion of GFP+/BFP+ cells (Fig. 4 C). At day 28 after transplantation, the percentage of GFP+/BFP+ cells was similar in both cohorts, but whereas 82% of the +RUNX1* mice developed AML by day 35, 83% of the mice receiving the 4-OHT pulse remained free of hematopoietic disease during a 100-d observation period (Fig. 4 D). Although only one animal in the pulse cohort developed fatal MPN disease, the majority of mice analyzed at the last time point presented with splenomegaly (Fig. 4 E). These results are consistent with the conclusion that maintenance of RUNX1 activation is necessary for the conversion of FLT3-ITD–induced MPN to AML.
To further investigate the importance of RUNX1 in disease maintenance, primary tumor cells were transplanted into conditioned recipients that were subjected to 4-OHT at day 0 or day 11 or left untreated (Fig. 4 F). Strikingly, whereas >80% of the transplanted mice treated at day 11 developed AML within 50 d, untreated mice remained healthy for >150 d (Fig. 4 G). Consistent with the negative impact of RUNX1 expression on transplantation efficiencies, mice receiving 4-OHT starting at day 0 failed to develop AML. Serial transplantations of the leukemic cells resulted in selection of variants that were capable of inducing AML with 100% penetrance in <25 d (Fig. 4 H). Together, these results demonstrate that RUNX1* together with FLT3-ITD induces a transplantable acute leukemia and, furthermore, that the expression of RUNX1 is necessary for maintenance of the disease.
Posttranslational modifications of RUNX1 are critical for stability and oncogenic activity
To investigate whether FLT3-ITD signaling impacts on RUNX1 activity in AML, we examined human AML cell lines reported to express FLT3-ITD. Consistent with our observation that RUNX1 transcript levels are higher in FLT3-ITD+ AML samples, we observed high RUNX1 protein levels in the FLT3-ITD+ cell line MV4;11. Only moderate levels of RUNX1 protein were observed in Molm13 cells, which carry but do not express the FLT3-ITD allele (Quentmeier et al., 2003), and K562 cells, which express the constitutive active BCR/ABL fusion kinase but do not exhibit FLT3 mutations (Fig. 5 A). Interestingly, expression levels of RUNX1-ER in AML cells isolated from our FLT3-ITD mouse models were similarly high as RUNX1 in MV4;11 cells (Fig. 5 B), although this finding needs to be strengthened by examining protein levels in primary AML cells. Strikingly, RUNX1 protein levels in MV4;11 cells were greatly reduced after 24-h treatment with FLT3 inhibitors but not with a MAPK inhibitor (Fig. 5 C). As RUNX1 stability/activity is highly dependent on phosphorylation (Goyama et al., 2015), we generated phosphorylation mutants in which residues targeted by downstream effectors of FLT3-ITD (e.g., MAPK or Src kinases) were altered (Fig. 5 D). Disruption of either Tyr or Ser/Thr phosphorylation sites within the negative regulatory DNA-binding domain of RUNX1 did not impact on RUNX1 sensitivity to Sunitinib treatment in FLT3-ITD–expressing cells. In contrast, mutants with disrupted Tyr phosphorylation sites within the inhibitory domain (ID) lost sensitivity to Sunitinib inhibition, suggesting these residues may be critical for FLT3-ITD–mediated activation of RUNX1 (Fig. 5 E).
To test more rigorously the impact of RUNX1 phosphorylation and its transforming activity in cooperation with FLT3-ITD, the RUNX1 phosphorylation mutants were tested in our in vivo model. In agreement with a critical role of Tyr phosphorylation within the ID domain, all mutants except the ID mutant induced a fatal AML (Fig. 5 F), despite comparable transduction levels and transplantation efficiencies of all constructs, as determined by flow cytometry analysis of PB cells (Fig. 5 G). Collectively, we identified key phosphorylation sites in RUNX1 that mediate its transforming activity in collaboration with FLT3-ITD.
High levels of RUNX1 are critical for maintenance of established human AML cells
To begin to assess whether our results obtained in a mouse system could be transferred to human AML, we asked whether decreasing the high levels of RUNX1 in MV4;11 cells by shRNA technology would impact on tumor formation in a xenograft mouse model. Two shRNAs were identified that, when expressed via a lentiviral vector coexpressing the Venus fluorescent protein, resulted in reduced RUNX1 protein levels (Fig. 6, A and B). Transduced MV4;11 cells with reduced RUNX1 levels showed a growth disadvantage in vitro using competition assays (Fig. 6 C). Finally, in contrast to control-transduced MV4;11 cells, shRNA-RUNX1–transduced cells failed to induce rapid, fatal tumorigenic growth in vivo (Fig. 6, D and E). It is unlikely that this effect is mediated by defective homing of shRNA-RUNX1 cells, as first, consistent with another study (Cai et al., 2011), we have not observed reduced homing in HSPCs lacking Runx1 (unpublished data), and second, CXCR4 expression levels were not reduced in MV4;11 cells expressing shRNA-RUNX1 (Fig. 6 F). Collectively, these results demonstrate the critical role of RUNX1 levels in the tumorigenic growth of FLT3-ITD AML.
Identification of RUNX1 target genes that block myeloid differentiation
In view of the critical role of activated RUNX1 in orchestrating the switch from an MPN phenotype to AML, we sought to identify critical RUNX1 target genes. AML cells with either a B6.Runx1Δ/+ or B6.Runx1Δ/Δ background were isolated from diseased mice and split into two cultures with or without 4-OHT. GFP+/BFP+ cells were sorted and used for transcriptome analysis. A total of 221 genes were significantly differentially expressed by greater than a factor of two in both experiments (Fig. 7 A). STRING analysis in combination with gene ontology (GO) term enrichment analysis was used to identify biological networks that reflect the deregulated genes (Fig. 7 B). Inactivating RUNX1 resulted in the striking up-regulation of genes implicated in Meg/Ery differentiation but also genes identified as regulators of innate immunity, which are predominantly expressed in mature G/M cells. These results are consistent with a critical role of RUNX1 in maintaining a block in myeloid differentiation. Consistently, down-regulated genes revealed a preponderance of factors involved in ribosome biogenesis, indicative of differentiating cells that are no longer proliferating (Wong et al., 2011a).
As a next step, we concentrated on deregulated genes encoding TF, as they are likely candidates for the observed differentiation block. The expression of a total of 1,620 genes encoding known TF was analyzed. 15 genes were identified whose expression was significantly up-regulated after RUNX1 inactivation in both AML samples, indicating that their expression was repressed by RUNX1* (Fig. 7 C, left). These include key regulators of Meg/Ery differentiation (Doré and Crispino, 2011; Kaufmann et al., 2012; Pimkin et al., 2014). In addition, several genes whose expression is up-regulated during G/M differentiation were also suppressed by RUNX1* (Fig. S3). In contrast, loss of RUNX1 activity led to the down-regulation of only a few transcriptional regulators (Fig. 7 C, right), including several genes implicated in the control of cell cycle (Myb and Mybbp1a) or direct downstream regulators of proliferation stimulus (e.g., Egr1, Mef2d, and Nop2). Two genes (Emx2 and Hhex) encoding homeotic box proteins belonging to the NK-like (NKL) subclass of ANTP homeobox genes were among the most strongly down-regulated genes after RUNX1 withdrawal.
HHEX is up-regulated in FLT3-ITD AML and by RUNX1 activation
Examination of AML patient databanks demonstrated that EMX2 expression was extremely low in both FLT3-ITDpos and FLT3-ITDneg patient samples (not depicted), but HHEX expression was high overall but with significantly higher expression observed in FLT3-ITDpos samples (Fig. 8 A). Thus, next, we determined whether the deregulation of the Hhex homeobox gene is directly mediated by RUNX1* and the importance of FLT3-ITD signaling in this deregulation. To confirm that Hhex is a direct target gene of Runx1, we interrogated Runx1 chromatin immunoprecipitation–binding data in G/M progenitor (GMP)–like FDC-P1 cells (Behrens et al., 2016) and hematopoietic stem cell (HSC)–like HPC7 cells (Wilson et al., 2010). Runx1-binding sites were observed in both HSC and GMP cell types and overlapped with binding sites for TFs specific for each cell type (e.g., Gfib or C/ebpα, respectively; Fig. 8 B). Next, we investigated whether RUNX1* induction and/or suppression of FLT3-ITD activity influenced Hhex gene expression in mouse cells. A twofold increase in Hhex expression was observed upon RUNX1 activation, but inhibiting FLT3-ITD activity with Sunitinib blocked RUNX1-mediated Hhex stimulation (Fig. 8 C). Together, these results demonstrate that RUNX1 binds to and up-regulates expression of the Hhex gene and that the former activity is augmented by FLT3-ITD signaling.
Hhex together with FLT3-ITD induces AML in vivo
To determine whether Hhex (or Emx2) is a critical effector of AML induction in RUNX1*/FLT3-ITD AML, retroviral transduction/transplantation experiments were performed (Figs. 9, A and B). The analysis of PB of transduced mice at regular intervals demonstrated the loss of single transduced Venus+ (HHEX or Emx2) cells with time, but a notable selective advantage of double-positive HHEX/FLT3-ITD cells but not Emx2/FLT3-ITD cells was observed at week 6 (Fig. 9 C). AML developed in 90% of HHEX/FLT3-ITD mice with a median latency of 86 d (Fig. 9 D). Moribund mice presented with hepatosplenomegaly and leukocytosis (Fig. 9 E). The high invasiveness of the neoplastic cells was confirmed in sections of BM, liver, spleen, and lungs (Fig. 9 F and Fig. S4). Flow cytometry confirmed an outgrowth of Venus+/BFP+ cells in both BM and spleen, with the majority of cells in the Venus+/BFP+ population being CD11b+Gr1−, indicative of a myeloid progenitor, in contrast to normal CD11b+Gr1+ myeloid precursor and mature cells found in uninfected BM (Figs. 9, G and H). Examination of blood films confirmed the high levels of blasts and also granulocytic progenitors, typical of AML-M2 with granulocytic differentiation (Fig. 9 I). Furthermore, transplantation capacity of the neoplastic cells in conditioned recipients was confirmed (Fig. 9 J). These results demonstrate that RUNX1* and FLT3-ITD signaling impair differentiation in part by maintaining high HHEX expression levels.
Mutations that lead to constitutive activation of FLT3 are among the most common genetic events in AML and are strongly associated with poor prognosis. A characteristic feature of AML is a differentiation blockade at an early stage of development, and efforts to identify mechanisms to reverse this block have been a long-standing aim of leukemia research, stimulated by the success of differentiation therapy in the treatment of acute promyelocytic leukemia (Nowak et al., 2009; de Thé and Chen, 2010). Our results reveal a hitherto uncharacterized synergy between the RUNX1 TF and FLT3-ITD mutations in the induction of AML. Notably, our study shows that Tyr phosphorylation of RUNX1 is an essential molecular switch for this oncogenic synergy and that RUNX1 is a central mediator of a differentiation block that is partially mediated by up-regulating the Hhex homeobox gene (Fig. 10). The findings gained from our mouse model are also likely translatable to human AML. RUNX1 RNA levels are strongly enhanced in human AML patients carrying FLT3-ITD, and its downstream target HHEX is specifically up-regulated in FLT3-ITD human AML samples. Furthermore, human AML cells engineered to suppress RUNX1 expression lose leukemogenic activity.
An oncogenic role of RUNX1 in AML was somewhat unexpected because of its well established function as tumor suppressor in this disease. A high occurrence of inactivating mutations has been observed in AML (Osato et al., 1999; Schnittger et al., 2011), and analyses of conditional Runx1-deficient mice have demonstrated alterations in the self-renewal capacity of HSPCs, leading to an expansion of the myeloid progenitor compartment, particularly in those skewed toward Meg differentiation (Ross et al., 2012; Lam et al., 2014; Behrens et al., 2016)—all evidence supporting a tumor suppressor function. Our study also supports a tumor suppressor function in the initiation phase of leukemia development, as indicated by a shorter latency in Runx1-deficient HSPCs. These results are supported by other studies that have demonstrated that Runx1-deficient cells show increased susceptibility to AML development (Jacob et al., 2010; Nishimoto et al., 2011). However, to our knowledge, this is the first study that demonstrates the dual tumor suppressor/oncogene function within the same cell system, although likely separated by temporal and spatial processes.
RUNX1 oncogenic activity is partly attributable to the up-regulation of the Hhex gene encoding an NKL-homeotic protein. NKL and HOX-like proteins comprise the antennapedia class of homeobox proteins, which are transcriptional regulators involved in many key developmental processes including cell-fate decisions. Although the central role of HOX-like genes in developmental hematopoiesis and leukemia is well established (Rawat et al., 2012), the importance of NKL genes is just now being realized (Homminga et al., 2012). HHEX plays a critical role in lymphoid development and early T cell progenitor ALL (George et al., 2003; Homminga et al., 2011; Jackson et al., 2015), and recent work has also uncovered its essential role in MLL-induced myeloid leukemia (Shields et al., 2016). It is of interest to note that differentiation stage impacted by HHEX versus RUNX1 transformation differed in that whereas RUNX1 blocked both G/M and Meg/Ery differentiation pathways, only the former was blocked in HHEX/FLT3-ITD AML. Thus, it is likely that suppression of genes encoding Meg/Ery TFs (e.g., LMO2, KLF1, and NFE2) is also a key oncogenic function of RUNX1. Interestingly, the recent work of two groups collaborate with our findings that high RUNX1 expression levels are associated with FLT3-ITD AML and have identified several additional candidate target genes (Cauchy et al., 2015; Hirade et al., 2016). Our system offers a viable system to validate their causal importance.
Although our expression analysis favors the importance of a RUNX1-induced differentiation blockade in defining the oncogenic mechanism, its oncogenic potential is likely attributable to additional mechanisms. Notably, RUNX1 inactivation in AML cells led to the down-regulation of several genes associated with ribosome biogenesis, consistent with results from a recent study demonstrating Runx1 regulation of this process in HSPCs (Cai et al., 2015). We postulate that activation of these genes by RUNX1 promotes sustained cell growth (Holland et al., 2004). However, we cannot rule out that up-regulation of genes involved in ribosome biogenesis reflects exit from the cell cycle through differentiation induction (Wong et al., 2011a). Interestingly, an oncogenic function of RUNX1 in mouse models of B and T cell lymphomas has been attributed to inhibiting p53 oncogene activity during stress response (Blyth et al., 2005; Kilbey et al., 2010). Furthermore, although the RUNX1 protein is not essential for myelopoiesis, recent studies have indicated that its expression is necessary and/or augments myeloid transformation by the RUNX1-RUNX1t1 and CBFβ/SMMHC (smooth muscle myosin heavy chain) fusion proteins (Ben-Ami et al., 2013; Goyama et al., 2013; Hyde et al., 2015; Mandoli et al., 2016). The ability of RUNX1 to inhibit apoptosis, either by up-regulation of Bcl2 or attenuation of the cell-cycle mitotic checkpoint, has been postulated to be the critical mechanism. Inhibiting apoptosis may contribute to the increased drug resistance observed in FLT3-ITD AML, which has recently been shown to correlate with RUNX1 expression (Hirade et al., 2016). Thus, RUNX1 likely exerts it oncogenic impact by a variety of overlapping mechanisms.
The unique association of FLT3-ITD mutations with AML as opposed to MPNs or myelodysplastic syndrome suggests a pivotal role in the differentiation block (Zheng and Small, 2005). Indeed, previous work has suggested that FLT3-ITD contributes to the block in myeloid differentiation through inhibiting the C/EBPα TF (Zheng and Small, 2005; Radomska et al., 2006). However, mouse models have demonstrated that Cebpa deficiency and FLT3-ITD expression are alone insufficient to induce AML (Reckzeh et al., 2012). An alternative or complimentary mechanism is suggested by our finding that RUNX1 protein levels are dependent on FLT3-ITD signaling in AML cells and that, together, they synergize to generate AML. High RUNX1 protein levels can be induced by several different mechanisms. Whereas our data support the hypothesis that FLT3 signaling impacts on protein levels via phosphorylation, the work of Cauchy et al. (2015) suggests that FLT3-ITD up-regulates RUNX1 gene expression directly. Reconcilable with either mechanism is the hypothesis that high RUNX1 levels may also reflect a selective process during FLT3-ITD leukemogenesis, by which RUNX1-high–expressing clones become dominant because of the synergistic interplay of these two pathways.
Finally, our study underlines the important impact of RUNX1 phosphorylation on its oncogenic activity. Decisions of cell fate are clearly regulated by signaling pathways through posttranslational modifications of key TFs. Yet, deciphering the intricate posttranslational code and its ultimate impact on cellular processes has been challenging. Phosphorylation, in particular, is known to promote or inhibit protein–protein interactions and thereby act as a molecular switch between cell fates. It is well established that FLT3-ITD activates Src kinases (Choudhary et al., 2009; Leischner et al., 2012), and Src has been shown to alter the activity of Runx1 through phosphorylation, presumably through altered interactions with TF regulators and chromatin modulators (e.g., SWI/SNF [switch/sucrose nonfermentable]; Huang et al., 2012). Our work demonstrated that Tyr phosphorylation within the ID region of RUNX1 is critical for its oncogenic potential, and thus, an important next step will be to identify potential coregulatory proteins that bind to this domain. Significantly, previous studies have shown that Tyr phosphorylation impairs Meg and T cell development but increases Runx1 stability and transactivation of Cebpa in myeloid cell lines (Huang et al., 2012; Leong et al., 2016).
The observation that inactivation of RUNX1 can promote differentiation of FLT3-ITD AML cells demonstrates that the leukemic stem cells have not acquired additional mutations that irrevocably alter their differentiation potential. These data suggest that therapies that can reverse this differentiation block will offer significant therapeutic efficacy in AML patients with FLT3-ITD mutations. This may include combination therapies that incorporate FLT3-ITD and Src inhibitors or small molecules that block RUNX1 phosphorylation or inhibit its function in regulating key target genes (Illendula et al., 2015). Considering the selective toxicity of Runx1 ablation to leukemic cells, but not to normal HSCs (Cai et al., 2011), inhibiting Runx1 may be a promising target for effective combination therapies in FLT3-ITD AML.
Materials and methods
Littermates from B6.Runx1fl/+-Tg(vav-Cre) X B6.Runx1fl/+ crosses were used for experiments (Behrens et al., 2016). B6.SJL-PtprcaPecb/BoyJ (B6-Ly.1) mice were used as hosts for BM transplantations. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from The Jackson Laboratory. All mice were maintained in a specific pathogen–free facility at the Heinrich-Pette-Institute animal facility. Animal experiments were approved by the Hamburg authorities and complied with the regulatory standards of the animal ethics committee.
HSPC transduction and transplantation
Standard mouse stem cell virus–based gamma-retroviral vectors were used to express (a) human RUNX1-ERt2 (Behrens et al., 2016), (b) human FLT3-ITD (Schmidt-Arras et al., 2005), and (c) human HHEX or mouse Emx2. Donor mice were injected with 150 mg/kg 5-fluoruracil (5-FU; Medac) 3 d before HSPC isolation. Transductions were performed as described previously (Schwieger et al., 2009). In brief, 3–5 × 105 HSPCs were co-transplanted with 5 × 104 spleen cells into lethally irradiated (9 Gy) B6-Ly.1 mice. RUNX1-ERt2 was induced in vivo at day 14 (pulse) or day 18 by administering tamoxifen citrate via standard food pellets (400 mg/kg; LASvendi LASCRDiets). For retransplantation assays, 5 × 106–107 tumor cells were injected in conditioned B6-Ly5.1 mice. In xenograft assays, 105 MV4;11 cells were intravenously transplanted into NSG mice.
Morphological and histological analysis of mice
Blood parameters were determined on a Hemavet 950 hematology system (Drew Scientific), and blood smears were stained according to the Pappenheim method (Sigma-Aldrich). Tissue samples of liver, lungs, and spleen were fixed in 4% (vol/vol) formalin and embedded in paraffin. Sterni were fixed in CALfix solution (Biocyc, Luckenwalde). Deparaffinized sections were stained with hematoxylin and eosin (H&E) or periodic acid Schiff solution (Sigma-Aldrich).
FDC-P1 (Dexter et al., 1980), MV4;11 (Quentmeier et al., 2003), and Molm 13 (Matsuo et al., 1997) cells were maintained as described previously. HSPCs and leukemic blasts were cultured in serum-free expansion media (StemSpan; STEMCELL Technologies) with 4 mM glutamine, 1 mM sodium pyruvate, 100 ng/ml mSCF, 100 ng/ml hIL-11, 100 ng/ml hFLT3L (PeproTech), and 10 ng/ml mIL-3 (Strathmann). RUNX1 activation was induced by culturing cells in 200 nM hydroxytamoxifen (Sigma-Aldrich). Inhibition of FLT3-ITD signaling was achieved by addition of Sunitinib (LC Laboratories) at the indicated concentration.
Cell purification and flow cytometry
For fluorescence-activated cell-sorter flow cytometry analysis and sorting, single-cell suspensions were prepared from blood, spleen, and BM. Erythrocytes were lysed (PharmLyse solution; BD), and cells were stained with fluorophore-conjugated antibodies (see Table S1 for list of antibodies) and analyzed or sorted on a FACS Canto II or Aria II (BD), respectively. Data acquisition and analysis were performed using FACS Diva software (BD).
Protein and RNA analyses
Proteins were extracted from cell pools with equal cell numbers using trichloroacetic acid and analyzed by Western blot analysis using standard procedures. See Table S2 for a list of antibodies used for analyses. For mRNA expression studies, total RNA was extracted using the peqGOLD TriFast kit (Peqlab). 1 µg RNA was used to generate cDNA libraries using TrueSeq RNA kits (Illumina). Sequencing was performed on a HiSeq 2500 sequencing system (Illumina). Reads were aligned to the mouse cDNA (genome browser version mm9; University of California, Santa Cruz), and reads per kilobase per million values were determined using the CLC_Genomic Workbench, with all parameters set to default settings. For illustration of deregulated genes, Venny 2.0.2 was used. Protein interaction network and enrichment analysis for GO terms (GO biological processes) were performed using STRING software (version 10; STRING Consortium). Networks were visualized using Cytoscape (version 3.2.0; Cytoscape Consortium). Heat maps were generated using GENE-E (version 3.0.204; Broad Institute). A comprehensive list of genes encoding TFs was obtained from the Riken Transcription Factor Database. RNA-Seq data from leukemic blasts have been deposited into the NCBI Gene Expression Omnibus portal under the accession no. GSE81422. For quantitative RT-PCR analysis, RNA was subjected to DNaseI digestion (Ambion) and converted to cDNA using avian myeloblastosis virus reverse transcriptase (New England Biolabs, Inc.). cDNA was used as a template for mRNA amplification by PowerSYBR Green PCR Master Mix (Roche; Applied Biosystems), run on a Light-Cycler 480 II system (Roche). Oligonucleotides are listed in Tables S3 and S4.
Online supplemental material
Figs. S1 and S4 contain additional histological results of diseased mice. Figs. S2 and S3 show heat maps of gene expression patterns in AML samples and normal hematopoiesis. Tables S1–S4 provide antibodies used for flow cytometry and Western blot analyses and oligo sequences for PCR and shRNA experiments.
We are indebted to Maike Täger and Marion Ziegler for assistance with animal experiments and cell culture, as well as Malik Alawi and Arne Düsedau for advice in questions of bioinformatics and flow cytometry, respectively. We also acknowledge the invaluable help of all members of the animal facilities of the Heinrich-Pette-Institute.
This work was funded by the Deutsche Krebshilfe Foundation. The Heinrich-Pette-Institute is supported by the Bundesministerium für Gesundheit and the Freie und Hansestadt Hamburg.
The authors declare no competing financial interests.
Author contributions: K. Behrens, K. Maul, N. Telkin, N. Kreibitzsch, D. Indenbirken, V. Prassolov, and U. Müller performed experiments and analyzed data. K. Behrens performed computational and statistical analysis. J. Cammenga and C. Stocking conceived the experiments and secured funding. K. Behrens and C. Stocking wrote the manuscript. H. Serve and J. Cammenga provided expertise and feedback.
acute lymphoblastic leukemia
acute myeloid leukemia
blue fluorescent protein
hematoxylin and eosin
hematopoietic stem cell
hematopoietic stem and progenitor cell
internal tandem duplication
K. Behrens’ present address is Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.